Overview

CP-690,550 and Midazolam Drug-Drug Interaction Study

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
CP-690,550 and midazolam are metabolized by similar enzymes in the liver. This study is designed to assess whether co-administration of CP-690,500 and midazolam will effect the metabolism of midazolam in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Midazolam
Tofacitinib